COMP <GO>
MDXG vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
MiMedx Group Inc (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MDXG 8
— JNJ 4
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MDXG
LAST: $3.97 (+0.51%) • MKT CAP: $579.3M
roic
47.20%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDXG VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDXG | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 82.60% | 67.90% | +14.70 | MDXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 47.20% | 25.50% | +21.70 | MDXG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.7x | 18.5x | -11.80 | MDXG | /valuation <GO> |
| Free Cash Flow Yield | 12.77% | 2.97% | +9.80 | MDXG | /fcf-yield <GO> |
| Operating Margin | 15.30% | 34.70% | -19.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 11.60% | 28.50% | -16.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 6.00% | +14.00 | MDXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.45 | 5.59 | +0.86 | MDXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | MDXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.9 | 62.1 | -29.23 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.0x | 23.0x | -13.00 | MDXG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $579.3M | $662.49B | -$661.91B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDXG REV | JNJ REV | MDXG GROSS % | JNJ GROSS % | MDXG FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $418.6M | $94.19B | 82.6% | 67.9% | $74.0M | $19.70B |
| FY 2024 | $348.9M | $88.82B | 82.8% | 69.1% | $66.2M | $19.84B |
| FY 2023 | $321.5M | $85.16B | — | — | $26.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDXG // BETA —
JNJ // BETA 1.08